Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details Textual)

v3.19.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 11, 2015
May 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Mar. 31, 2019
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2017
Clinical and Development Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           $ 7,100,000          
Neupharma [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment of Upfront Fees         $ 1,000,000            
Reimbursement Of Cost Recognized As Revenue           0   $ 31,000      
Neupharma [Member] | Additional Sales Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           40,000,000          
Neupharma [Member] | Clinical and Development Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           40,000,000          
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           22,500,000          
Dana-Farber [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Shares Issued, Price Per Share $ 0.065                    
Stock Issued During Period, Shares, Issued for Services 500,000     136,830              
Stock Issued During Period, Value, Issued for Services $ 32,500     $ 600,000              
Payment of Upfront Fees         1,000,000            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 5.00%                    
Cash In Exchange For Common Stock $ 10,000,000                    
Payment For Non refundable Milestone payments             $ 1,000,000        
Maintenance Fee                 $ 50,000    
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           21,500,000          
Maximum Potential Milestone Payments                 21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due                 $ 60,000,000    
Maximum Potential Milestone Payments           60,000,000          
Teva Pharmaceutical Industries Ltd [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment of Upfront Fees     $ 500,000                
Jubilant Biosys Ltd [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment of Upfront Fees                   $ 2,000,000  
Revenue Recognition, Milestone Method, Revenue Recognized           $ 11,000   268,000      
Research and Development Cost, Shared Percentage           50.00%          
Non-Refundable Milestone Payment                     $ 400,000
Proceeds from Upfront Fees   $ 1,000,000                  
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           $ 89,000,000          
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           59,500,000          
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           61,700,000          
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           89,000,000          
Maximum Potential Milestone Payments           89,000,000          
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           87,200,000          
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Maximum Potential Milestone Payments           4,800,000          
Collaboration Agreement With TGTX [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition, Milestone Method, Revenue Recognized           341,000   $ 44,000      
Proceeds from Upfront Fees         $ 500,000            
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           7,000,000          
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           14,500,000          
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Revenue Recognition Milestone Method, Payments Due           $ 25,500,000